Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)
Nirmal Ghati, Sushma Bhatnagar, Manjit Mahendran, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
Eliano Pio Navarese, Przemysław Podhajski, Paul A. Gurbel, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 3, pp. 224-234
Open Access | Times Cited: 50
The bidirectional interaction of COVID-19 infections and lipoproteins
Kenneth R. Feingold
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 4, pp. 101751-101751
Open Access | Times Cited: 19
Statins in hospitalized COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials
Yajuan Ren, Guizuo Wang, Dong Han
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access | Times Cited: 15
Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial
Hajar Shokri‐Afra, Sudabe Baghery moghadam, Ziaeddin Oladi, et al.
Journal of Reports in Pharmaceutical Sciences (2025) Vol. 13, Iss. 1
Open Access
High density lipoproteins and COVID-19: preparing the next pandemic
Marie Laurine Apalama, Floran Bègue, Sébastien Tanaka, et al.
Journal of Lipid Research (2025), pp. 100779-100779
Open Access
Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review
Carles Vilaplana-Carnerero, Maria Giner‐Soriano, Ángela Domı́nguez, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1206-1206
Open Access | Times Cited: 14
Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Cynthia Florêncio de Mesquita, André Rivera, Beatriz Araújo, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 10, pp. 966-973.e11
Closed Access | Times Cited: 4
Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial
Naglaa Hamdi Eltahan, Neamat Hamdy Elsawy, Kholoud M. Abdelaaty, et al.
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Effects of statin therapy in hospitalized adult COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials
Débora Pinheiro Xavier, Gabriel Cavalcante Lima, Lorena Gisele Ferreira Gomes, et al.
Einstein (São Paulo) (2023) Vol. 21
Open Access | Times Cited: 9
Antiplatelet agents for the treatment of adults with COVID-19
Anna-Lena Fischer, Sarah Messer, Rachel Riera, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 9
COVID-19 and the Response to Antiplatelet Therapy
Tomáš Bolek, Matej Samoš, Jakub Jurica, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 2038-2038
Open Access | Times Cited: 7
The impact of statin therapy on in‐hospital prognosis and endothelial function of patients at high‐to‐very high cardiovascular risk admitted for COVID‐19
Vanessa Bianconi, Massimo R. Mannarino, Elena Cosentini, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 7
Prior Statin vs In-Hospital Statin Usage in Severe COVID-19: Review and Meta-Analysis
Iad Alhallak, Hakan Paydak, Jawahar L. Mehta
Current Problems in Cardiology (2023) Vol. 48, Iss. 9, pp. 101810-101810
Open Access | Times Cited: 6
Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations
Beatrice A. Golomb, Junhee Han, Peter H. Langsjoen, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 14, pp. 4659-4659
Open Access | Times Cited: 6
Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials
Amirmohammad Khalaji, Amir Hossein Behnoush, Sanam Alilou, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 5
The effect of anti-platelet agents on end organ dysfunction and mortality in community acquired pneumonia: A protocol for a systematic review and meta-analysis
Sylvain Lother, Lana Tennenhouse, Rasheda Rabbani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data
Adovich S. Rivera, Omar Al-Heeti, Matthew J. Feinstein, et al.
BMJ Open (2024) Vol. 14, Iss. 10, pp. e085547-e085547
Open Access | Times Cited: 1
Treating COVID-19: Targeting the Host Response, Not the Virus
David S. Fedson
Life (2023) Vol. 13, Iss. 3, pp. 712-712
Open Access | Times Cited: 4
Association of Cardiovascular Medications With Adverse Outcomes in a Matched Analysis of a National Cohort of Patients With COVID-19
Leonard Kuan‐Pei Wang, Yong‐Fang Kuo, Jordan Westra, et al.
American Journal of Medicine Open (2023) Vol. 9, pp. 100040-100040
Open Access | Times Cited: 4
Analogies between COVID-19 and Preeclampsia: Focus on Therapies
Valentina Giardini, Carlo Gambacorti‐Passerini, Marco Casati, et al.
International Journal of Translational Medicine (2023) Vol. 3, Iss. 2, pp. 203-216
Open Access | Times Cited: 4
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics
Denise Battaglini, Fernanda F. Cruz, Chiara Robba, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 995-1015
Closed Access | Times Cited: 6
Aspirin and P2Y12 inhibitors in treating COVID-19
Amirmohammad Khalaji, Amir Hossein Behnoush, Soheil Peiman
European Journal of Internal Medicine (2022) Vol. 110, pp. 101-103
Open Access | Times Cited: 5
Statins - From Lipid-Lowering Benefits to Pleiotropic Effects

IntechOpen eBooks (2023)
Open Access | Times Cited: 2
Coagulopathy in severe COVID-19 patients: causes, concerns and current treatment regimen
Tanusree Sengupta, Arun Luiz, C. Suganthi, et al.
Acta Haematologica Polonica (2024)
Open Access
The association of antiplatelet agents with mortality among patients with non-COVID-19 community-acquired pneumonia: A systematic review and meta-analysis
Sylvain Lother, Lana Tennenhouse, Rasheda Rabbani, et al.
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 8, Iss. 5, pp. 102526-102526
Open Access
Page 1 - Next Page

Scroll to top